NASDAQ •
Healthcare •
Biotechnology •
Quote as of 05/08/2026
Company Profile
IndustryBiotechnology
SectorHealthcare
ExchangeNASDAQ
Market Capitalization78.1 mln
Float3.85 mln
Earnings Date05/08/2026
Piotroski F-Score
2
/ 9
Weak
1-Year Forecast
14.00
Limited downside
Relative Strength
100
/ 100
Top performer
Debt / Equity
0.00
Debt-free
ROE
-66.98
Deeply negative
Dividend Yield
0.00%
No dividend
Business Description
Edesa Biotech is a Canadian biopharmaceutical company focused on developing treatments for inflammatory and immune-related conditions, with a pipeline that includes both injectable antibody therapies and topical creams. Its most advanced programs target serious conditions such as acute respiratory distress syndrome, chronic skin allergies, and pulmonary fibrosis, with several candidates already in late-stage clinical trials. The company works alongside research partners in Switzerland and Israel to broaden the reach of its drug development efforts across human and animal health applications. Founded in 2015 and based in Markham, Ontario, Edesa continues to advance its portfolio from early research through to potential commercialization.